p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.

Mutations in the TP53 suppressor gene are frequent in breast cancers. These mutations are associated with poor prognosis, thought to be due to proliferative advantage and poor response to chemotherapy associated with loss of p53 function. The focal adhesion kinase (FAK/PTK2), a tyrosine kinase, is over-expressed in a variety of human tumors including breast cancers. FAK is a critical regulator of adhesion and motility and its over-expression is associated with increased metastatic potential. Recently, FAK promoter has been shown to contain p53 responsive elements and to be down-regulated by DNA-damage in a p53-dependent manner. Here, we have used five estrogen-dependent breast cancer cells lines with different p53 status, including an isogenic model, to show that FAK expression was regulated in a p53-dependent manner in response to estradiol. FAK protein and mRNA expression were down-regulated by estradiol in wild-type but not mutant p53 cells. Moreover, silencing wild-type p53 increased FAK expression, while over expressing p53 repressed FAK expression. ChIP experiment showed that p53 bound to FAK promoter in the presence of estradiol in p53 wild-type but not in mutant p53 cells, suggesting a direct role of p53 in down regulating FAK mRNA expression. FAK mRNA expression was also found to correlate with TP53 mutation status in a series of breast tumors. Finally, loss of FAK down-regulation in p53 mutant cells was correlated with increased proliferation and invasion upon estradiol stimulation, while FAK silencing reduced invasion. These results suggest that p53 is an important down regulator of FAK and that loss of p53 function in breast cancer may contribute to the metastatic potential of estrogen-responsive tumors through uncontrolled FAK expression upon estrogens stimulation.

[1]  S. Hanks,et al.  Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases , 1995, Molecular and cellular biology.

[2]  S. Jhanwar,et al.  Hormonal regulation of tumor suppressor proteins in breast cancer cells , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  Wenjun Guo,et al.  Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.

[4]  F. Kittrell,et al.  Hormone dependence in premalignant mammary progression. , 2003, Cancer research.

[5]  D. Schlaepfer,et al.  Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.

[6]  J. Bergh,et al.  The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  J. Depasquale,et al.  Decreased tyrosine phosphorylation of focal adhesion kinase after estradiol treatment of MCF-7 human breast carcinoma cells , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[8]  C. Prives,et al.  Blinded by the Light: The Growing Complexity of p53 , 2009, Cell.

[9]  B. van de Water,et al.  Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.

[10]  V. Golubovskaya,et al.  Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. , 2004, Biochimica et biophysica acta.

[11]  Neil O. Carragher,et al.  The role of focal-adhesion kinase in cancer — a new therapeutic opportunity , 2005, Nature Reviews Cancer.

[12]  P. Hainaut,et al.  Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB , 2006, Oncogene.

[13]  Bei Wang,et al.  Redefining the p53 response element , 2009, Proceedings of the National Academy of Sciences.

[14]  M. Planas-Silva,et al.  Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. , 2006, Biochemical and biophysical research communications.

[15]  W. Muller,et al.  Multifaceted Roles of Integrins in Breast Cancer Metastasis , 2007, Journal of Mammary Gland Biology and Neoplasia.

[16]  P. Hainaut,et al.  25 years of p53 research , 2005 .

[17]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[18]  S. Grant,et al.  Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. , 2004, Genes & development.

[19]  Joseph Geradts,et al.  High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype , 2005, Modern Pathology.

[20]  Hongjuan Zhao,et al.  TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer , 2007, Breast Cancer Research.

[21]  M. Olivier,et al.  Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines , 2010, Breast Cancer Research and Treatment.

[22]  V. Golubovskaya,et al.  p53 regulates FAK expression in human tumor cells , 2008, Molecular carcinogenesis.

[23]  Francesca Storici,et al.  Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence , 2002, Molecular and Cellular Biology.

[24]  F. Wright,et al.  Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  W. Cance,et al.  Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. , 1995, Cancer research.

[26]  C. Turner,et al.  Tyrosine phosphorylation of paxillin and pp125FAK accompanies cell adhesion to extracellular matrix: a role in cytoskeletal assembly , 1992, The Journal of cell biology.

[27]  E. Shaulian,et al.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding , 1992, Molecular and cellular biology.

[28]  A. Børresen-Dale,et al.  Prognostic and Predictive Value of TP53 Mutations in Human Cancer , 2007 .

[29]  P. Conte,et al.  The curability of breast cancer and the treatment of advanced disease , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[30]  S. Conrad,et al.  c-Myc Suppresses p21WAF1/CIP1 Expression during Estrogen Signaling and Antiestrogen Resistance in Human Breast Cancer Cells* , 2005, Journal of Biological Chemistry.

[31]  Bob van de Water,et al.  Focal adhesion kinase: a potential target in cancer therapy. , 2007, Biochemical pharmacology.

[32]  R. Eeles,et al.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.

[33]  R. Millikan,et al.  FAK overexpression and p53 mutations are highly correlated in human breast cancer , 2009, International journal of cancer.